Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREATH trial of buspirone for chemoreflex modulation and central apnea in heart failure
2015-005383-42Phase 2Completed
- Sponsor
- Fondazione Toscana Gabriele Monasterio
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of buspirone in heart failure (HF) and central sleep apnea (CSA) (2 arms), sponsored by Fondazione Toscana Gabriele Monasterio. Started Jan 2019; status: completed.
02
Drugs
buspirone
03
Conditions
heart failure (HF)central sleep apnea (CSA)
Beyond the preview
Go deeper on 2015-005383-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005383-42.